LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 22.5% in December

LAVA Therapeutics (NASDAQ:LVTX) saw a significant decline in short interest in December. As of December 31st, there was short interest totalling 45,500 shares, a decline of 22.5% from the December 15th total of 58,700 shares. Based on an average daily trading volume, of 112,000 shares, the short-interest ratio is presently 0.4 days. Currently, 0.3% of the company’s stock are sold short.

LAVA Therapeutics Trading Down 1.0 %

Shares of LVTX stock traded down $0.01 during trading hours on Wednesday, reaching $0.97. 23,198 shares of the company’s stock were exchanged, compared to its average volume of 144,040. LAVA Therapeutics has a 1 year low of $0.88 and a 1 year high of $6.47. The stock has a market cap of $24.59 million, a PE ratio of -0.94 and a beta of 0.56. The stock’s fifty day moving average price is $1.35 and its two-hundred day moving average price is $1.65.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Leerink Partners reiterated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Leerink Partnrs cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. HC Wainwright reduced their price objective on shares of LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, December 20th. Finally, JMP Securities restated a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.33.

Institutional Trading of LAVA Therapeutics

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in shares of LAVA Therapeutics in the third quarter worth $32,000. Pathway Financial Advisors LLC increased its holdings in LAVA Therapeutics by 70.8% in the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after buying an additional 42,500 shares during the period. Finally, XTX Topco Ltd purchased a new position in LAVA Therapeutics during the 2nd quarter worth approximately $55,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.